Elevance Health's Financial Rebound Anticipated in 2027

by : Natalie Pace

Elevance Health (ELV) is poised for a significant financial recovery in 2027, according to Greenskeeper Asset Management's Q2 2026 report. Following a period of heightened medical costs, the company's profitability is projected to improve, with operating margins bottoming out in 2026. This positive outlook is supported by stable cost trends, favorable government reimbursement adjustments, and the inherent strength of ELV's commercial health insurance business.

Elevance Health Set for Robust Earnings Recovery in 2027

In its Q2 2026 investor letter, Greenskeeper Asset Management, an independent firm specializing in disciplined value investing, showcased Elevance Health, Inc. (NYSE: ELV) as a key driver of its portfolio's performance. As of August 3, 2026, the US-based health benefits company traded at $382.77 per share, commanding a market capitalization of $81.54 billion. While ELV experienced a one-month return of -8.61%, its shares demonstrated a notable 38.48% gain over the past 52 weeks.

The firm highlighted that Elevance Health's profitability is starting to rebound after facing challenges from elevated medical cost inflation within its government-sponsored insurance plans. Although medical utilization remains high, cost trends have stabilized, providing a more predictable financial landscape. Moreover, government reimbursement updates have been more favorable than initially expected.

Greenskeeper Asset Management forecasts that 2026 will represent the lowest point for operating margins. The subsequent year, 2027, is anticipated to bring a substantial earnings recovery, fueled by disciplined repricing strategies and an enhanced alignment between premiums and medical expenses. The investment thesis underpinning this optimistic view rests on the enduring strength of ELV's commercial health insurance franchise, which consistently performs well and forms a resilient bedrock for the company's long-term earning potential.

Elevance Health's trajectory offers a compelling narrative for investors focusing on the healthcare sector. The company's ability to navigate a complex cost environment and adapt to regulatory changes underscores its resilience. For stakeholders, the projected recovery in 2027, coupled with the stability of its core insurance operations, signals a period of renewed growth and value creation.

Argenx SE Expands Vyvgart's Reach in Autoimmune Disease Treatment
by : Vicki Robin
Argenx SE Expands Vyvgart's Reach in Autoimmune Disease Treatment
Baron Capital's Q2 2026 investor letter highlights Argenx SE's progress with Vyvgart, an FcRn inhibitor. The company aims to demonstrate its efficacy across a wider spectrum of autoimmune conditions, showing promise in clinical trials and maintaining a strong pipeline. This development comes despite leadership changes, reinforcing investor confidence in its future growth.
learn more
The Enduring Principle of Long-Term Investment Success
by : JL Collins
The Enduring Principle of Long-Term Investment Success
This article explores the core principle shared by the most successful investors throughout history: eschewing market timing in favor of a consistent, long-term approach. Drawing on historical data and expert analysis, it demonstrates the inherent difficulty and low probability of consistently profiting from short-term market fluctuations, highlighting how staying invested, even through volatile periods, ultimately leads to greater wealth accumulation.
learn more
Olin Corp. Poised for Recovery Amidst Chlor-alkali Market Shift
by : Dave Ramsey
Olin Corp. Poised for Recovery Amidst Chlor-alkali Market Shift
Olin Corporation (OLN) is expected to see a stock recovery driven by a tightening chlor-alkali market, despite recent underperformance. A Q2 2026 investor letter from Hotchkis & Wiley Mid-Cap Value Fund highlights the company's strong position as a major producer of chlor-alkali chemicals, anticipating increased demand and pricing. The company's strategic merger with Huntsman and commitment to a strong balance sheet further support its potential for growth.
learn more
Palantir Stock Soars on AI Platform Success and Strong Earnings
by : Dave Ramsey
Palantir Technologies experienced a significant stock surge of over 27% following its latest quarterly earnings report. The company's Artificial Intelligence Platform (AIP), launched in 2023, is credited as a major catalyst for this growth, integrating large language models with existing data analysis platforms, Gotham and Foundry. This innovation has attracted major clients and boosted profitability, positioning Palantir as a leader in enterprise AI.
Humana's Strategic Recovery and Growth Trajectory
by : JL Collins
Humana Inc. demonstrated strong performance in Q2 2026, benefiting from increased Medicare Advantage payments. Despite previous undervaluation due to high utilization and reimbursement rate uncertainties, the company is poised for margin recovery through annual repricing. This analysis, from Hotchkis & Wiley's investor letter, highlights Humana's resilience and potential for sustained growth in the healthcare sector.
Creative Culinary Uses for Leftover Cucumbers
by : Michele Borba
Discover ten inventive recipes to transform forgotten cucumbers into delightful dishes. From zesty pickles and refreshing salads to unique cocktails and savory sauces, this guide helps you minimize food waste and maximize flavor. Embrace culinary creativity and give those neglected cucumbers a delicious second life.
Reflections on Postpartum Depression: Five Years Later
by : Adele Faber
Five years after experiencing postpartum depression (PPD), the author shares crucial insights she wishes she had known before childbirth. She delves into the profound impact of hormonal shifts, the complexities of breastfeeding, the deceptive allure of social media for new mothers, and the vital importance of community support. This reflective piece underscores the necessity of mental health preparedness for new parents.